Effectiveness of metyrapone in treating Cushing

Introduction
Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating effective biochemical control (1) . Where a cause amenable to surgical intervention is identified, surgery at a center with appropriate expertise is the optimum management. Nevertheless, many patients need urgent control of severe or persisting hypercortisolemia.
Options for medical treatment include steroidogenesis enzyme inhibitors suitable for all causes of CS (ketoconazole, metyrapone, mitotane), agents to suppress ACTH in Cushing's disease (CD), such as dopamine agonists and pasireotide, and the glucocorticoid receptor antagonist, mifepristone (2, 3) .
The modern use of ketoconazole has recently been reported in a multicenter French Study (4) , although its availability in the United States has been restricted following an FDA safety warning for hepatotoxicity in 2013 (5, 6 ), but it is widely available in Europe in 2015 (7).
The cortisol-lowering effect of metyrapone was described as early as 1958 by Liddle and co-workers, with later reports confirming metyrapone as a potent inhibitor of the steroidogenesis enzyme 11β-hydroxylase (8, 9) . Since then, it has been used as a diagnostic test of adrenal reserve and to treat the hypercortisolism of CS. Despite its widespread use, data on metyrapone are scarce, with the largest study to date (including 91 patients) being published over 25 years ago (10) . Here, we have assessed the effectiveness of metyrapone therapy in a contemporary series of patients with CS, by performing a retrospective study of patients treated in the UK. The same proforma was used in all centers to record anonymized data. Data were gathered from case records and electronic record systems. Baseline, demographic and safety data, the indication for treatment and dose of metyrapone therapy, any therapeutic intervention and any recorded adverse events were documented. Monitoring tests included early morning (09.00h) serum cortisol, 24-hour urinary free cortisol (UFC), serum potassium, plasma ACTH and serum cortisol 'day-curves' (CDC). In CDCs multiple samples for serum cortisol are collected across the day with the mean calculated (11) . All tests performed during the monitoring period were collected and analyzed. All centers used immunoassay-based cortisol assays.
Patients were treated either with a dose titration regimen i.e. metyrapone dose was up-titrated according to response to achieve a biochemical target for cortisol, or a block-and-replace regimen where the dose of metyrapone was quickly up-titrated to achieve blockade of cortisol synthesis and a replacement dose of glucocorticoid was added to provide background physiological levels.
Biochemical targets for treatment (eucortisolemia) were defined as a mean CDC value of 150-300nmol/l (10.9μg/dl), which has been shown to equate to a normal cortisol production rate as assessed by stable isotopic methodology (11), a UFC level below the upper limit of normal (ULN) for the assay used or a 09.00h serum cortisol within target. Although 09.00h serum cortisol is occasionally being used as a sole test for evaluating patients' response to treatment there is currently no standardized agreement for what values of this test represent appropriate control. Two different levels of target 09.00h cortisol were therefore assessed; (i) below the upper limit of normal for the assay used, or less than 600nmol/l (21.7μg/dl) if the ULN was higher than this value, and (ii), a recommended value of 331nmol (12.0μg/dl) (12) . Cortisol levels were reported in nmol/L and divided by 27.59 to calculate the equivalent value in μg/dl. There was a wide range of UFC assays used with variable reference range of normal values; therefore UFC values were converted to multiples of the upper limit of normal (ULN) for the assay and this value was used for statistical comparisons. Patients with sufficient monitoring data (i.e. at least one test as described above repeated at least twice during the study period) were included in the efficacy analysis. For the efficacy analyses we compared the mean values at each monitoring test (CDC, 09.00h serum cortisol, UFC) before treatment to (i) the mean values on the last review on treatment (diagnosis vs. last review), and (ii) the mean of all tests performed in all patients during treatment (diagnosis vs. treatment), unless otherwise stated. The change of the biochemical markers between (i) baseline (at diagnosis/ pre-treatment) and the last review on treatment for 09.00h cortisol, and (ii) the first and the last biochemical review for CDCs (CDCs were not routinely performed prior to initiation of treatment) on treatment was also analyzed.
Statistical analysis was performed using the two-tailed Student's t test (GraphPad prism 6.0, GraphPad Software Inc., La Jolla, USA). Except where stated, values given are means +/-standard deviations. A p-value of less than 0.05 was considered significant. The study was approved as an institutional case notes review at each participating center.
Results
Baseline characteristics
One hundred and ninety-five patients were treated with metyrapone across the 13 centers. The majority of patients had CD (115 patients, 37 macroadenoma) with the remainder having ectopic ACTH syndrome (EAS, 37), adrenocortical carcinoma (ACC, 10), and benign adrenal disease [30 adrenal adenoma (AA), ACTH-independent macronodular adrenal hyperplasia (2) and primary pigmented nodular adrenal hyperplasia (1)] (Table 1) were controlled (for dose see Table 2 ).
At the time of the first normalization, 91% were treated with dose titration and 9% with block-and-replace. In ACTH-dependent disease plasma ACTH levels were measured too sporadically to allow meaningful analysis. 10/18 (56%) patients who did not achieve a biochemical target also had a reduction of cortisol levels.
Metyrapone monotherapy as secondary treatment
Thirty-one patients (29 CD, 1 EAS, 1 benign adrenal disease) received metyrapone as secondary treatment following either surgery (21) 
Long-term treatment with metyrapone monotherapy
Monitoring data were available on 38 patients who received metyrapone monotherapy for longer than 6 months. The average duration of treatment was 18.6 months and 6 patients had block-and-replace at some point during their treatment. Starting and final dose (Table 2) Mean, median and range of doses on metyrapone monotherapy at the initiation of treatment and at final review are shown in Table 2 . On 'block-andreplace' the starting dose of metyrapone was higher (mean dose 1432mg vs.
939.2mg, p<0.0001). There were, however, no significant differences in the mean 09.00h serum cortisol levels during treatment or at the last review in the No subgroup analysis for efficacy was performed for this group due to small numbers.
Safety considerations
Side effects were noted in 48/195 patients (25%): 88% were managed as outpatients, whereas 12% (7/57 events) required either admission for evaluation or prolongation of a current admission. The rate of adverse events in patients on therapy for >6months was 11% (4/38 patients). There were no pregnant women, and no deaths recorded due to an adverse event. The average dose of metyrapone at the time of an adverse event was 1600mg.
Gastrointestinal upset (23%) and hypoadrenalism (7% -symptoms of dizziness, hypotension, with biochemical confirmation) were the most common side effects. Most adverse events (39/56) occurred within 15 days of initiation of metyrapone or after a dose increase. Gastrointestinal upset and dizziness were the main reasons for discontinuing treatment. Patients with confirmed hypoadrenalism were managed either by addition of glucocorticoid (regimen change to a block-and-replace) or temporary cover with glucocorticoid and simultaneous reduction of metyrapone dose. In 15% of cases the metyrapone dose was reduced. In 12 cases (23%) metyrapone was withdrawn temporarily or permanently, with 11/12 showing full resolution, and in one symptoms continued but became less severe -muscle aches at presentation worsened during metyrapone therapy but returned to pretreatment levels after drug withdrawal. Symptoms of hyperandrogenism were not frequent; hirsutism was not reported and there was only one case of worsening acne during treatment. Similarly edema was only reported in one case but the causative drug was thought to be a calcium channel blocker.
Hypoglycemia was reported in three patients on diabetic medications and was associated with improvement of hypercortisolism.
Potassium levels were monitored and actively treated at presentation and during therapy. In 138 patients on metyrapone monotherapy, with no other treatment interventions for their CS, mean potassium levels increased from 3.68nmol/L to 3.90nmol/L (p=0.003) during treatment ( Figure 3 ).
Discussion
We report the effectiveness of metyrapone in clinical practice for the treatment of CS. To our knowledge this is the largest study of metyrapone use as either monotherapy or metyrapone in combination with other cortisol-lowering medications. Overall more than 80% of patients showed an improvement in levels of circulating cortisol with over 50% achieving biochemical eucortisolemia when on monotherapy when assessed by the stringent criterion of control on a CDC. It is likely that additional therapies were added because of the severity of disease and clinician preference, but the retrospective and multicenter nature of our study precludes a formal assessment of this. Furthermore, our data support that metyrapone monotherapy is an effective treatment for hypercortisolemia either before or after surgical intervention to the primary cause of CS.
Metyrapone is widely used in CS in the UK and other countries but less so in the USA. To date, the efficacy of metyrapone in reducing cortisol levels in CS has been described in case reports and small case series (13) (14) (15) (16) , with the largest series reported 25 years ago by Verhelst et al (10) . In this single center experience, metyrapone was effective in reducing cortisol levels in 75% of 91 patients with CD, EAS and ACC based on a mean CDC level <400nmol/L that is higher than the more stringent <300nmol/L level that we used in this study. Most patients in the Verhelst study received a short course of metyrapone except for 24 patients who had metyrapone for a median of 27 months following radiotherapy to the pituitary gland. Smaller studies have reported the efficacy of metyrapone in patients with CD undergoing radiotherapy (13) (14) (15) and EAS (17) . Overall, in 200 cases of metyrapone monotherapy published in the English literature, biochemical control was achieved in 75% (18) . We report similar efficacy. It is of note, however, that the majority of patients with CD in our study here were not treated in conjunction with pituitary radiotherapy, and there did not appear to be evidence of an escape of control phenomenon, although we cannot comment on plasma ACTH levels during monitoring.
Ketoconazole, an antifungal agent and inhibitor of adrenal steroidogenesis, has also been widely used as a cortisol-lowering agent in CS. In the largest report to date, Castinetti et al reported biochemical control in 50% of patients with CS treated with ketoconazole monotherapy with biochemical improvement in 75% and evidence of regression of clinical features in up to 60% (4). Overall, in 456 published cases treated with ketoconazole monotherapy, 60% achieved control (18) . Combination treatment with metyrapone and ketoconazole is commonly used (19) , especially for the rapid control of hypercortisolism prior to definite treatment. In 22 patients with severe hypercortisolism due to EAS (n=14) and ACC (n=8), combination treatment of metyrapone and ketoconazole dramatically improved UFC levels within a month of treatment, while half of the patients also started mitotane during this time (20) . Kamenicky et al used a triple-medication protocol with simultaneous administration of ketoconazole, metyrapone and mitotane in 11 patients with hypercortisolism and life-threatening complications as an alternative to bilateral adrenalectomy; all patients showed rapid clinical and biochemical improvement (21) . In both studies, the initial biochemical control is mainly due to the combination of ketoconazole and metyrapone as the onset of action of mitotane is usually delayed by several weeks due to accumulation in adipose tissue (22) . In one of the few prospective studies of medical treatment of CD, Feelders et al used a stepwise approach to treat 17 patients with CD with a combination of pituitary and adrenal-acting agents.
Patients were initially treated with the somatostatin analog pasireotide, followed by cabergoline, and ketoconazole was later introduced if biochemical control was suboptimal. Nine out of 17 patients normalized with pasireotide/ cabergoline and ketoconazole induced biochemical control in 6/8 remaining patients (75%) within 20 days of treatment (23) .
Metyrapone increases cortisol metabolites in the serum and urine due to the predominant inhibition of 11β-hydroxylase, and to a lesser extent the other steroidogenesis enzymes (10, 24) . In particular, 11-deoxycortisol levels may become profoundly elevated in patients on metyrapone therapy, especially in patients with CD (25, 26) . 11-deoxycortisol is structurally very similar to cortisol and may cross-react with cortisol immunoassays resulting in an overestimation of serum cortisol values in patients on metyrapone (26, 27) .
The importance of this is underscored by the fact that symptoms of adrenal insufficiency may overlap those of side effects of metyrapone. Thus, cortisol estimation by more accurate methods such as mass spectrometry is preferable and should be used where available (28) . Moreover, it is likely that our data may underestimate the efficacy of metyrapone therapy when assessing serum measurements of cortisol as the cross-reactivity in immunoassays results in approximate 20% elevated bias (25) .
Hypokalemia has been described as a potential serious complication of metyrapone therapy (24, 29) due to the increase in steroid precursors with mineralocorticoid activity (11-deoxycorticosterone) . Our data suggest clinicians using metyrapone are well aware of the importance of monitoring and managing serum potassium levels since we found that these increase significantly with supportive measures during treatment. It is important to stress, however, that such active monitoring is required, as hypokalemia is also a potentially harmful feature of CS. The most common adverse effects observed were mild gastrointestinal symptoms and hypoadrenalism, the latter a positive response to treatment provided that it is recognized and managed early. Patients on long-term treatment are more likely those who tolerate metyrapone well, therefore the rate of adverse events was favorable in this subgroup. Interestingly, hirsutism was not reported.
This study carries the limitations imposed by its retrospective design. been used, and therefore we can only speculate that the overall control when using this criterion might have been better if applied in practice.
In conclusion, our data show that metyrapone is effective and safe in treating hypercortisolemia in patients with Cushing's syndrome. showed an improvement). b), Change in the pre-treatment 09.00h cortisol level in 123 patients treated with metyrapone monotherapy and the last review on treatment: 86% showed an improvement; 102 (83%) patients had a 09.00h serum cortisol value below the ULN for the assay used or 600nmol/L (whichever was lowest) and 69 (56%) had a 09.00h level<331nmol/L.
Figure 3
Potassium levels before and during metyrapone monotherapy in 138 patients. 
